<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077870</url>
  </required_header>
  <id_info>
    <org_study_id>ACT2847g</org_study_id>
    <nct_id>NCT00077870</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Multicenter, Blinded Phase I/II Study of the Safety of Escalating Doses of Ocrelizumab (PRO70769) in Subjects With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, multicenter, blinded Phase I/II, investigator and
      subject-blinded study of the safety of escalating doses of ocrelizumab in combination with
      MTX in subjects with moderate to severe RA
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ocrelizumab in subjects with moderate to severe RA</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ocrelizumab</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of ocrelizumab</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical responses according to American College of Rheumatology (ACR) criteria</measure>
  </secondary_outcome>
  <enrollment>237</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ocrelizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability and willingness to provide written informed consent and to comply with the
             requirements of the protocol

          -  Diagnosis of RA for at least 6 months according to the revised 1987 ACR criteria for
             the classification of RA

          -  Positive serum RF

          -  Current treatment for RA on an outpatient basis

          -  Contact your local site that is listed for more inclusion criteria

        Exclusion Criteria:

          -  Bone or joint surgery (including joint fusion) within 8 weeks prior to screening or
             joint surgery planned within 24 weeks after randomization

          -  Rheumatic autoimmune disease other than RA or significant systemic involvement
             secondary to RA (e.g., vasculitis, pulmonary fibrosis, or Feltyï¿½s syndrome)

          -  Functional Class IV as defined by the ACR classification of functional status in RA

          -  History of or current inflammatory joint disease other than RA (e.g., gout, reactive
             arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or
             other systemic rheumatic disorders (e.g., systemic lupus erythematosus, inflammatory
             bowel disease, scleroderma, inflammatory myopathy, overlap syndrome)

          -  Contact your local site that is listed for more exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Dummer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W; ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008 Sep;58(9):2652-61. doi: 10.1002/art.23732.</citation>
    <PMID>18759293</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2004</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>September 1, 2009</last_update_submitted>
  <last_update_submitted_qc>September 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2009</last_update_posted>
  <keyword>Moderate to severe rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

